Pharma Mar, S.A. (PHMMF)
USD 88.18
(-16.49%)
USD 88.18
(-16.49%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 152.36 Million EUR | 8.64% |
| 2022 | 138.26 Million EUR | 14.23% |
| 2021 | 121.04 Million EUR | 21.0% |
| 2020 | 100.03 Million EUR | 2.0% |
| 2019 | 98.06 Million EUR | -30.18% |
| 2018 | 140.44 Million EUR | -7.2% |
| 2017 | 151.35 Million EUR | -2.78% |
| 2016 | 155.67 Million EUR | 14.65% |
| 2015 | 135.78 Million EUR | 44.97% |
| 2014 | 93.66 Million EUR | 6.43% |
| 2013 | 88 Million EUR | 0.84% |
| 2012 | 87.27 Million EUR | -17.2% |
| 2011 | 105.4 Million EUR | -9.92% |
| 2010 | 117.01 Million EUR | 4.75% |
| 2009 | 111.7 Million EUR | 8.22% |
| 2008 | 103.22 Million EUR | 11.51% |
| 2007 | 92.57 Million EUR | 1.9% |
| 2006 | 90.84 Million EUR | 924.44% |
| 2005 | 8.86 Million EUR | -5.36% |
| 2004 | 9.37 Million EUR | -86.52% |
| 2003 | 69.52 Million EUR | -9.91% |
| 2002 | 77.18 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 41.13 Million EUR | -4.85% |
| 2024 Q3 | 38.18 Million EUR | -5.78% |
| 2024 Q2 | 40.5 Million EUR | -1.53% |
| 2023 FY | 150.21 Million EUR | 8.64% |
| 2023 Q4 | 43.23 Million EUR | 23.51% |
| 2023 Q3 | 35 Million EUR | -12.49% |
| 2023 Q2 | 40 Million EUR | 15.94% |
| 2023 Q1 | 34.5 Million EUR | -24.23% |
| 2022 FY | 138.26 Million EUR | 14.23% |
| 2022 Q1 | 30.33 Million EUR | -18.63% |
| 2022 Q2 | 34.4 Million EUR | 13.43% |
| 2022 Q4 | 45.53 Million EUR | 62.63% |
| 2022 Q3 | 28 Million EUR | -18.61% |
| 2021 Q3 | 30.47 Million EUR | 17.37% |
| 2021 FY | 121.04 Million EUR | 21.0% |
| 2021 Q1 | 27.32 Million EUR | 11.27% |
| 2021 Q2 | 25.96 Million EUR | -4.95% |
| 2021 Q4 | 37.27 Million EUR | 22.3% |
| 2020 FY | 100.03 Million EUR | 2.0% |
| 2020 Q1 | 26.86 Million EUR | 26.71% |
| 2020 Q3 | 25.41 Million EUR | 9.55% |
| 2020 Q4 | 24.55 Million EUR | -3.4% |
| 2020 Q2 | 23.2 Million EUR | -13.62% |
| 2019 Q2 | 25.34 Million EUR | -6.97% |
| 2019 Q4 | 21.19 Million EUR | -12.71% |
| 2019 Q1 | 27.23 Million EUR | -17.42% |
| 2019 Q3 | 24.28 Million EUR | -4.16% |
| 2019 FY | 98.06 Million EUR | -30.18% |
| 2018 Q1 | 36.49 Million EUR | -5.34% |
| 2018 Q4 | 32.98 Million EUR | 12.87% |
| 2018 Q2 | 41.74 Million EUR | 14.4% |
| 2018 Q3 | 29.22 Million EUR | -29.99% |
| 2018 FY | 140.44 Million EUR | -7.2% |
| 2017 Q1 | 35.98 Million EUR | -12.63% |
| 2017 Q4 | 38.54 Million EUR | 2.6% |
| 2017 FY | 151.35 Million EUR | -2.78% |
| 2017 Q3 | 37.57 Million EUR | -4.27% |
| 2017 Q2 | 39.24 Million EUR | 9.09% |
| 2016 Q4 | 41.18 Million EUR | 9.83% |
| 2016 FY | 155.67 Million EUR | 14.65% |
| 2016 Q2 | 39.52 Million EUR | 5.45% |
| 2016 Q3 | 37.49 Million EUR | -5.12% |
| 2016 Q1 | 37.47 Million EUR | -30.05% |
| 2015 Q1 | 19.4 Million EUR | -29.22% |
| 2015 FY | 135.78 Million EUR | 44.97% |
| 2015 Q4 | 53.58 Million EUR | 111.04% |
| 2015 Q3 | 25.38 Million EUR | -32.12% |
| 2015 Q2 | 37.4 Million EUR | 92.73% |
| 2014 Q4 | 27.41 Million EUR | 2.12% |
| 2014 FY | 93.66 Million EUR | 6.43% |
| 2014 Q3 | 26.84 Million EUR | -11.8% |
| 2014 Q2 | 30.44 Million EUR | 239.77% |
| 2014 Q1 | 8.95 Million EUR | -63.71% |
| 2013 Q3 | 27.22 Million EUR | -5.0% |
| 2013 Q4 | 24.68 Million EUR | -9.33% |
| 2013 FY | 88 Million EUR | 0.84% |
| 2013 Q1 | 7.42 Million EUR | -86.27% |
| 2013 Q2 | 28.66 Million EUR | 285.79% |
| 2012 Q3 | 28.63 Million EUR | 172.12% |
| 2012 FY | 87.27 Million EUR | -17.2% |
| 2012 Q1 | 28.97 Million EUR | -18.3% |
| 2012 Q2 | 10.52 Million EUR | -63.68% |
| 2012 Q4 | 54.11 Million EUR | 88.99% |
| 2011 Q1 | 28.99 Million EUR | -8.16% |
| 2011 Q4 | 35.46 Million EUR | 10.12% |
| 2011 FY | 105.4 Million EUR | -9.92% |
| 2011 Q3 | 32.2 Million EUR | 1.07% |
| 2011 Q2 | 31.86 Million EUR | 9.88% |
| 2010 Q1 | 25.43 Million EUR | -34.0% |
| 2010 Q2 | 30.02 Million EUR | 18.05% |
| 2010 FY | 117.01 Million EUR | 4.75% |
| 2010 Q3 | 29.98 Million EUR | -0.12% |
| 2010 Q4 | 31.57 Million EUR | 5.28% |
| 2009 Q3 | 25.49 Million EUR | -15.15% |
| 2009 Q1 | 17.63 Million EUR | -34.52% |
| 2009 Q2 | 30.04 Million EUR | 70.41% |
| 2009 FY | 111.7 Million EUR | 8.22% |
| 2009 Q4 | 38.53 Million EUR | 51.13% |
| 2008 Q4 | 26.93 Million EUR | -7.71% |
| 2008 Q3 | 29.17 Million EUR | 33.35% |
| 2008 Q2 | 21.88 Million EUR | -13.3% |
| 2008 Q1 | 25.23 Million EUR | 0.0% |
| 2008 FY | 103.22 Million EUR | 11.51% |
| 2007 FY | 92.57 Million EUR | 1.9% |
| 2006 FY | 90.84 Million EUR | 924.44% |
| 2005 FY | 8.86 Million EUR | -5.36% |
| 2004 FY | 9.37 Million EUR | -86.52% |
| 2003 FY | 69.52 Million EUR | -9.91% |
| 2002 FY | 77.18 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioxytran, Inc. | 3.82 Million USD | -3888.511% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -75.568% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -58116.226% |
| SQZ Biotechnologies Company | 85.61 Million USD | -77.959% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -5124.785% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -415.572% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -308.977% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -10044.956% |
| Marizyme, Inc. | 19.23 Million USD | -691.935% |
| Genus plc | 147.7 Million USD | -3.16% |
| Pharming Group N.V. | 225.49 Million USD | 32.429% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -7337.235% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -11257.577% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1727.162% |
| ContraFect Corporation | 56.88 Million USD | -167.832% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -10203.756% |
| IMV Inc. | 37.7 Million USD | -304.058% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -5360.484% |
| ONE Bio Corp. | 6.44 Million USD | -2264.518% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -77.284% |
| Mesoblast Limited | 5.9 Million USD | -2481.616% |
| MultiCell Technologies, Inc. | 567.42 USD | -26852495.961% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -516.496% |
| Genscript Biotech Corporation | 825.34 Million USD | 81.539% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -39011.986% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -5698.886% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2998.204% |
| Biomind Labs Inc. | 994.18 Thousand USD | -15225.866% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -8558.8% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -2168.036% |
| Skye Bioscience, Inc. | 13.54 Million USD | -1024.683% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -8072.573% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1635.539% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 609568.0% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -3356.075% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -2921.929% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -851.685% |
| Accustem Sciences Inc. | 3.74 Million USD | -3967.004% |
| EV Biologics, Inc. | 531.96 Thousand USD | -28542.459% |
| Q BioMed Inc. | 3.43 Million USD | -4333.619% |
| GB Sciences, Inc. | 1.42 Million USD | -10626.226% |
| Alpha Cognition Inc. | 9.7 Million USD | -1469.887% |
| CSL Limited | 3.44 Billion USD | 95.582% |
| Agentix Corp. | 1.37 Million USD | -11007.442% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -53.394% |
| Enzolytics Inc. | 2.17 Million USD | -6890.893% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 12.71 Million USD | -1098.608% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -4073.63% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -8202.949% |
| argenx SE | 1.53 Billion USD | 90.064% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -165.263% |
| HST Global, Inc. | 140.9 Thousand USD | -108033.024% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -14494.54% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -13444.817% |
| Halberd Corporation | 74.84 Thousand USD | -203484.885% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -6235.6% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -4374.829% |
| Zenith Capital Corp. | 8.94 Million USD | -1603.757% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -9547.419% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -6105.594% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1984.289% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -88739.07% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -7832.038% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -874516.842% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -6076.804% |
| Helix BioMedix, Inc. | 1.97 Million USD | -7626.388% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -1302.107% |
| Kadimastem Ltd | 2.41 Million USD | -6221.988% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -563.192% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -83855.699% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -11309.575% |
| LadRx Corporation | 3.81 Million USD | -3897.255% |
| Cell Source, Inc. | 4.32 Million USD | -3422.655% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -36572.612% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -16398.684% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -16398.684% |
| Affymax, Inc. | 39.38 Million USD | -286.856% |
| Mobile Lads Corp. | 554.54 Thousand USD | -27375.989% |
| Itoco Inc. | 919.14 Thousand USD | -16477.072% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -3494.906% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -13516.354% |
| International Stem Cell Corporation | 5.27 Million USD | -2790.666% |
| CytoDyn Inc. | 18.05 Million USD | -743.765% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -605275.661% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -69133.181% |
| Qrons Inc. | 643.67 Thousand USD | -23571.344% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -10631.642% |
| SYBLEU INC | 160.87 Thousand USD | -94610.833% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -6732.972% |
| Rebus Holdings, Inc. | 664 Thousand USD | -22846.837% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -8288.775% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -289339.991% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -748889.825% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -320.137% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -9316.996% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -20606.68% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -4797.686% |
| Neutra Corp. | 243.82 Thousand USD | -62391.336% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -772.813% |
| PureTech Health plc | 144.59 Million USD | -5.374% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -643.62% |
| IXICO plc | 4.7 Million USD | -3137.03% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1632.034% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -29.401% |
| CSL Limited | 3.89 Billion USD | 96.086% |
| Cellectis S.A. | 97.32 Million USD | -56.563% |